Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease

Science Translational Medicine

Volumn 4, Issue 141, 2012, Pages

  Cooper, Oliver ^a   Seo, Hyemyung ^a   Andrabi, Shaida ^b   Guardia Laguarta, Cristina ^c   Graziotto, John ^d   Sundberg, Maria ^a   McLean, Jesse R ^a   Carrillo Reid, Luis ^e   Xie, Zhong ^e   Osborn, Teresia ^a   Hargus, Gunnar ^a   Deleidi, Michela ^a   Lawson, Tristan ^a   Bogetofte, Helle ^a   Perez Torres, Eduardo ^a   Clark, Lorraine ^c   Moskowitz, Carol ^c   Mazzulli, Joseph ^d   Chen, Li ^b   Volpicelli Daley, Laura ^f   Romero, Norma ^c   Jiang, Houbo ^g   Uitti, Ryan J ^h   Huang, Zhigao ⁱ   Opala, Grzegorz ^j   Scarffe, Leslie A ^b   Dawson, Valina L ^b   Klein, Christine ^k   Feng, Jian ^g   Ross, Owen A ^h   Trojanowski, John Q ^f   Lee, Virginia M Y ^f   Marder, Karen ^c   Surmeier, D James ^e   Wszolek, Zbigniew K ^h   Przedborski, Serge ^c   Krainc, Dimitri ^d   Dawson, Ted M ^b   Isacson, Ole ^a,l   more..

^a MCLEAN HOSPITAL   (United States)

^b Institute for Cell Engineering   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j MEDICAL UNIVERSITY OF SILESIA   (Poland)

^k UNIVERSITY OF LÜBECK   (Germany)

^l Hanyang University   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; LEUCINE RICH REPEAT KINASE 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; UBIDECARENONE; 5 IODO 3 ((3,5 DIBROMO 4 HYDROXYPHENYL)METHYLENE) 2 INDOLINONE; 5-IODO-3-((3,5-DIBROMO-4-HYDROXYPHENYL)METHYLENE)-2-INDOLINONE; INDOLE DERIVATIVE; LRRK2 PROTEIN, HUMAN; PHENOL DERIVATIVE; PROTEIN SERINE THREONINE KINASE; UBIQUINONE;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL MOTION; CELLULAR STRESS RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FAMILY HISTORY; FEMALE; FIBROBLAST; GENE; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; LRRK2 GENE; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NERVE CELL; PARKINSON DISEASE; PHENOTYPE; PINK1 GENE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTON RADIATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY;

HUMANS; INDOLES; INDUCED PLURIPOTENT STEM CELLS; MITOCHONDRIA; NEURONS; PARKINSON DISEASE; PHENOLS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; UBIQUINONE;

EID: 84863584524     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003985     Document Type: Article

References (71)

1. C. Y. Chung, H. Seo, K. C. Sonntag, A. Brooks, L. Lin, O. Isacson, Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 14, 1709-1725 (2005).
2. J. N. Guzman, J. Sanchez-Padilla, D. Wokosin, J. Kondapalli, E. Ilijic, P. T. Schumacker, D. J. Surmeier, Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696-700 (2010).
3. T. G. Lesnick, S. Papapetropoulos, D. C. Mash, J. Ffrench-Mullen, L. Shehadeh, M. de Andrade, J. R. Henley, W. A. Rocca, J. E. Ahlskog, D. M. Maraganore, A genomic pathway approach to a complex disease: Axon guidance and Parkinson disease. PLoS Genet. 3, e98 (2007).
4. J. W. Langston, P. Ballard, J. W. Tetrud, I. Irwin, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980 (1983).
5. J. M. Gorell, C. C. Johnson, B. A. Rybicki, E. L. Peterson, R. J. Richardson, The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 1346-1350 (1998).
6. J. Simón-Sánchez, C. Schulte, J. M. Bras, M. Sharma, J. R. Gibbs, D. Berg, C. Paisan-Ruiz, P. Lichtner, S. W. Scholz, D. G. Hernandez, R. Krüger, M. Federoff, C. Klein, A. Goate, J. Perlmutter, M. Bonin, M. A. Nalls, T. Illig, C. Gieger, H. Houlden, M. Steffens, M. S. Okun, B. A. Racette, M. R. Cookson, K. D. Foote, H. H. Fernandez, B. J. Traynor, S. Schreiber, S. Arepalli, R. Zonozi, K. Gwinn,M. van der Brug, G. Lopez, S. J. Chanock, A. Schatzkin, Y. Park, A. Hollenbeck, J. Gao, X. Huang, N. W. Wood, D. Lorenz, G. Deuschl, H. Chen, O. Riess, J. A. Hardy, A. B. Singleton, T. Gasser, Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312 (2009).
7. M. R. Cookson, O. Bandmann, Parkinson's disease: Insights from pathways. Hum. Mol. Genet. 19, R21-R27 (2010).
8. J. Hardy, Genetic analysis of pathways to Parkinson disease. Neuron 68, 201-206 (2010).
9. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R. J. Uitti, D. B. Calne, A. J. Stoessl, R. F. Pfeiffer, N. Patenge, I. C. Carbajal, P. Vieregge, F. Asmus, B. Müller-Myhsok, D. W. Dickson, T. Meitinger, T. M. Strom, Z. K. Wszolek, T. Gasser, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004).
10. C. Paisán-Ruíz, S. Jain, E. W. Evans, W. P. Gilks, J. Simón, M. van der Brug, A. López de Munain, S. Aparicio, A. M. Gil, N. Khan, J. Johnson, J. R. Martinez, D. Nicholl, I. M. Carrera, A. S. Pena, R. de Silva, A. Lees, J. F.Martí-Massó, J. Pérez-Tur, N. W. Wood, A. B. Singleton, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004).
11. J. O. Aasly, M. Toft, I. Fernandez-Mata, J. Kachergus, M. Hulihan, L. R. White, M. Farrer, Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann. Neurol. 57, 762-765 (2005).
12. D. G. Healy, M. Falchi, S. S. O'Sullivan, V. Bonifati, A. Durr, S. Bressman, A. Brice, J. Aasly, C. P. Zabetian, S. Goldwurm, J. J. Ferreira, E. Tolosa, D. M. Kay, C. Klein, D. R. Williams, C. Marras, A. E. Lang, Z. K. Wszolek, J. Berciano, A. H. Schapira, T. Lynch, K. P. Bhatia, T. Gasser, A. J. Lees, N. W. Wood; International LRRK2 Consortium, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurol. 7, 583-590 (2008).
13. A. S. Chen-Plotkin, W. Yuan, C. Anderson, E. McCarty Wood, H. I. Hurtig, C. M. Clark, B. L. Miller, V. M. Lee, J. Q. Trojanowski, M. Grossman, V. M. Van Deerlin, Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70, 521-527 (2008).
14. B. I. Giasson, J. P. Covy, N. M. Bonini, H. I. Hurtig, M. J. Farrer, J. Q. Trojanowski, V. M. Van Deerlin, Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315-322 (2006).
15. B. D. Lee, J. H. Shin, J. VanKampen, L. Petrucelli, A. B. West, H. S. Ko, Y. I. Lee, K. A. Maguire-Zeiss, W. J. Bowers, H. J. Federoff, V. L. Dawson, T. M. Dawson, Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 16, 998-1000 (2010).
16. M. R. Cookson, The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 11, 791-797 (2010).
17. E.M. Valente, P.M.Abou-Sleiman, V. Caputo, M.M. Muqit, K. Harvey, S. Gispert, Z.Ali, D.Del Turco, A. R. Bentivoglio, D. G. Healy, A. Albanese, R. Nussbaum, R. González-Maldonado, T. Deller, S. Salvi, P. Cortelli, W. P. Gilks, D. S. Latchman, R. J. Harvey, B. Dallapiccola, G. Auburger, N. W. Wood, Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004).
18. E. M. Valente, A. R. Bentivoglio, P. H. Dixon, A. Ferraris, T. Ialongo, M. Frontali, A. Albanese, N. W. Wood, Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68, 895-900 (2001).
19. Y. Hatano, K. Sato, B. Elibol, H. Yoshino, Y. Yamamura, V. Bonifati, H. Shinotoh, M. Asahina, S. Kobayashi, A. R. Ng, R. L. Rosales, S. Hassin-Baer, Y. Shinar, C. S. Lu, H. C. Chang, Y. H. Wu-Chou, F. B. Ataç, T. Kobayashi, T. Toda, Y. Mizuno, N. Hattori, PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 63, 1482-1485 (2004).
20. Y. Hatano, Y. Li, K. Sato, S. Asakawa, Y. Yamamura, H. Tomiyama, H. Yoshino, M. Asahina, S. Kobayashi, S. Hassin-Baer, C. S. Lu, A. R. Ng, R. L. Rosales, N. Shimizu, T. Toda, Y. Mizuno, N. Hattori, Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol. 56, 424-427 (2004).
21. K. Hedrich, J. Hagenah, A. Djarmati, A. Hiller, T. Lohnau, K. Lasek, A. Grünewald, R. Hilker, S. Steinlechner, H. Boston, N. Kock, C. Schneider-Gold, W. Kress, H. Siebner, F. Binkofski, R. Lencer, A. Münchau, C. Klein, Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: Role of a single hit? Arch. Neurol. 63, 833-838 (2006).
22. M. Kasten, C. Weichert, K. Lohmann, C. Klein, Clinical and demographic characteristics of PINK1 mutation carriers - A meta-analysis. Mov. Disord. 25, 952-954 (2010).
23. W. Satake, Y. Nakabayashi, I. Mizuta, Y. Hirota, C. Ito, M. Kubo, T. Kawaguchi, T. Tsunoda, M. Watanabe, A. Takeda, H. Tomiyama, K. Nakashima, K. Hasegawa, F. Obata, T. Yoshikawa, H. Kawakami, S. Sakoda, M. Yamamoto, N. Hattori, M. Murata, Y. Nakamura, T. Toda, Genomewide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307 (2009).
24. Y. J. Edwards, G. W. Beecham, W. K. Scott, S. Khuri, G. Bademci, D. Tekin, E. R. Martin, Z. Jiang, D. C. Mash, J. ffrench-Mullen, M. A. Pericak-Vance, N. Tsinoremas, J. M. Vance, Identifying consensus disease pathways in Parkinson's disease using an integrative systems biology approach. PLoS One 6, e16917 (2011).
25. C. Klein, R. Chuang, C. Marras, A. E. Lang, The curious case of phenocopies in families with genetic Parkinson's disease. Mov. Disord. 26, 1793-1802 (2011).
26. M. A. Israel, S. H. Yuan, C. Bardy, S. M. Reyna, Y. Mu, C. Herrera, M. P. Hefferan, S. Van Gorp, K. L. Nazor, F. S. Boscolo, C. T. Carson, L. C. Laurent, M. Marsala, F. H. Gage, A. M. Remes, E. H. Koo, L. S. Goldstein, Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216-220 (2012).
27. P. Seibler, J. Graziotto, H. Jeong, F. Simunovic, C. Klein, D. Krainc, Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J. Neurosci. 31, 5970-5976 (2011).
28. C. Vives-Bauza, C. Zhou, Y. Huang, M. Cui, R. L. de Vries, J. Kim, J. May, M. A. Tocilescu, W. Liu, H. S. Ko, J. Magrané,D. J.Moore, V. L. Dawson, R.Grailhe, T.M.Dawson, C. Li, K. Tieu, S. Przedborski, PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U.S.A. 107, 378-383 (2010).
29. V. S. Van Laar, B. Arnold, S. J. Cassady, C. T. Chu, E. A. Burton, S. B. Berman, Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization. Hum. Mol. Genet. 20, 927-940 (2011).
30. 2+-dependent mitochondrial contraction. Cell Calcium 46, 18-29 (2009).
31. +)-ATPases - Nature's most versatile proton pumps. Nat. Rev. Mol. Cell Biol. 3, 94-103 (2002).
32. S. Dröse, K. U. Bindseil, E. J. Bowman, A. Siebers, A. Zeeck, K. Altendorf, Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. Biochemistry 32, 3902-3906 (1993).
33. A. V. Zhdanov, R. I. Dmitriev, D. B. Papkovsky, Bafilomycin A1 activates respiration of neuronal cells via uncoupling associated with flickering depolarization of mitochondria. Cell. Mol. Life Sci. 68, 903-917 (2011).
34. V. V. Teplova, A. A. Tonshin, P. A. Grigoriev, N. E. Saris, M. S. Salkinoja-Salonen, Bafilomycin A1 is a potassium ionophore that impairs mitochondrial functions. J. Bioenerg. Biomembr. 39, 321-329 (2007).
35. A. Grünewald, G. J. Breedveld, K. Lohmann-Hedrich, C. F. Rohé, I. R. König, J. Hagenah, N. Vanacore, G. Meco, A. Antonini, S. Goldwurm, S. Lesage, A. Dürr, F. Binkofski, H. Siebner, A. Münchau, A. Brice, B. A. Oostra, C. Klein, V. Bonifati, Biological effects of the PINK1 c.1366C>T mutation: Implications in Parkinson disease pathogenesis. Neurogenetics 8, 103-109 (2007).
36. A. S. Divakaruni, M. D. Brand, The regulation and physiology of mitochondrial proton leak. Physiology 26, 192-205 (2011).
37. A. B. West,D. J. Moore, S. Biskup, A. Bugayenko, W. W. Smith, C. A. Ross, V. L. Dawson, T. M.Dawson, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842-16847 (2005).
38. G. Morfini, G. Pigino, K. Opalach, Y. Serulle, J. E. Moreira, M. Sugimori, R. R. Llinás, S. T. Brady, 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 104, 2442-2447 (2007).
39. A. R. Saha, J. Hill, M. A. Utton, A. A. Asuni, S. Ackerley, A. J. Grierson, C. C. Miller, A. M. Davies, V. L. Buchman, B. H. Anderton, D. P. Hanger, Parkinson's disease a-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci. 117, 1017-1024 (2004).
40. C. Y. Chung, J. B. Koprich, H. Siddiqi, O. Isacson, Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV a-synucleinopathy. J. Neurosci. 29, 3365-3373 (2009).
41. L. S. Goldstein, Z. Yang, Microtubule-based transport systems in neurons: The roles of kinesins and dyneins. Annu. Rev. Neurosci. 23, 39-71 (2000).
42. F. Gillardon, Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - A point of convergence in parkinsonian neurodegeneration? J. Neurochem. 110, 1514-1522 (2009).
43. B. Frei, M. C. Kim, B. N. Ames, Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc. Natl. Acad. Sci. U.S.A. 87, 4879-4883 (1990).
44. P. C. Chin, L. Liu, B. E. Morrison, A. Siddiq, R. R. Ratan, T. Bottiglieri, S. R. D'Mello, The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J. Neurochem. 90, 595-608 (2004).
45. B. Dehay, J. Bové, N. Rodríguez-Muela, C. Perier, A. Recasens, P. Boya, M. Vila, Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30, 12535-12544 (2010).
46. C. Malagelada, Z. H. Jin, V. Jackson-Lewis, S. Przedborski, L. A. Greene, Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J. Neurosci. 30, 1166-1175 (2010).
47. C. Malagelada, Z. H. Jin, L. A. Greene, RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J. Neurosci. 28, 14363-14371 (2008).
48. L. S. Tain, H. Mortiboys, R. N. Tao, E. Ziviani, O. Bandmann, A. J. Whitworth, Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12, 1129-1135 (2009).
49. H. Mortiboys, K. K. Johansen, J. O. Aasly, O. Bandmann, Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75, 2017-2020 (2010).
50. C. Piccoli, A. Sardanelli, R. Scrima, M. Ripoli, G. Quarato, A. D'Aprile, F. Bellomo, S. Scacco, G. De Michele, A. Filla, A. Iuso, D. Boffoli, N. Capitanio, S. Papa, Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation. Neurochem. Res. 33, 2565-2574 (2008).
51. A. Rakovic, A. Grünewald, P. Seibler, A. Ramirez, N. Kock, S. Orolicki, K. Lohmann, C. Klein, Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum. Mol. Genet. 19, 3124-3137 (2010).
52. A. Rakovic, A. Grünewald, J. Kottwitz, N. Brüggemann, P. P. Pramstaller, K. Lohmann, C. Klein, Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS One 6, e16746 (2011).
53. P. Damier, E. C. Hirsch, Y. Agid, A. M. Graybiel, The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122, 1437-1448 (1999).
54. D. J. Brooks, Examining Braak's hypothesis by imaging Parkinson's disease. Mov. Disord. 25 (Suppl. 1), S83-S88 (2010).
55. A. Bender, K. J. Krishnan, C. M. Morris, G. A. Taylor, A. K. Reeve, R. H. Perry, E. Jaros, J. S. Hersheson, J. Betts, T. Klopstock, R. W. Taylor, D. M. Turnbull, High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515-517 (2006).
56. Y. Kraytsberg, E. Kudryavtseva, A. C. McKee, C. Geula, N. W. Kowall, K. Khrapko, Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 38, 518-520 (2006).
57. A. Colman, O. Dreesen, Pluripotent stem cells and disease modeling. Cell Stem Cell 5, 244-247 (2009).
58. K. Saha, R. Jaenisch, Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 5, 584-595 (2009).
59. L. L. Rubin, Stem cells and drug discovery: The beginning of a new era? Cell 132, 549-552 (2008).
60. Z. K. Wszolek, R. F. Pfeiffer, Y. Tsuboi, R. J. Uitti, R. D. McComb, A. J. Stoessl, A. J. Strongosky, A. Zimprich, B. Müller-Myhsok, M. J. Farrer, T. Gasser, D. B. Calne, D. W. Dickson, Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62, 1619-1622 (2004).
61. L. Ishihara, L. Warren, R. Gibson, R. Amouri, S. Lesage, A. Dürr, M. Tazir, Z. K. Wszolek, R. J. Uitti, W. C. Nichols, A. Griffith, N. Hattori, D. Leppert, R. Watts, C. P. Zabetian, T. M. Foroud, M. J. Farrer, A. Brice, L. Middleton, F. Hentati, Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch. Neurol. 63, 1250-1254 (2006).
62. E. M. Chan, S. Ratanasirintrawoot, I. H. Park, P. D. Manos, Y. H. Loh, H. Huo, J. D. Miller, O. Hartung, J. Rho, T. A. Ince, G. Q. Daley, T. M. Schlaeger, Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat. Biotechnol. 27, 1033-1037 (2009).
63. G. L. Boulting, E. Kiskinis, G. F. Croft, M. W. Amoroso, D. H. Oakley, B. J. Wainger, D. J. Williams, D. J. Kahler, M. Yamaki, L. Davidow, C. T. Rodolfa, J. T. Dimos, S. Mikkilineni, A. B. Macdermott, C. J. Woolf, C. E. Henderson, H. Wichterle, K. Eggan, A functionally characterized test set of human induced pluripotent stem cells. Nat. Biotechnol. 29, 279-286 (2011).
64. M. Deleidi, G. Hargus, P. Hallett, T. Osborn, O. Isacson, Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. Stem Cells 29, 1052-1063 (2011).
65. H. Deng, W. Le, Y. Guo, C. B. Hunter, W. Xie, M. Huang, J. Jankovic, Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J. Neurol. Sci. 251, 102-106 (2006).
66. O. Cooper, G. Hargus, M. Deleidi, A. Blak, T. Osborn, E. Marlow, K. Lee, A. Levy, E. Perez-Torres, A. Yow, O. Isacson, Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol. Cell. Neurosci. 45, 258-266 (2010).
67. M. Frank-Kamenetsky, X. M. Zhang, S. Bottega, O. Guicherit, H. Wichterle, H. Dudek, D. Bumcrot, F. Y. Wang, S. Jones, J. Shulok, L. L. Rubin, J. A. Porter, Small-molecule modulators of Hedgehog signaling: Identification and characterization of Smoothened agonists and antagonists. J. Biol. 1, 10 (2002).
68. J. K. Chen, J. Taipale, K. E. Young, T. Maiti, P. A. Beachy, Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. U.S.A. 99, 14071-14076 (2002).
69. C. Y. Chung, H. Seo, K. C. Sonntag, A. Brooks, L. Lin, O. Isacson, Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 14, 1709-1725 (2005).
70. J. Pruszak, W. Ludwig, A. Blak, K. Alavian, O. Isacson, CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells 27, 2928-2940 (2009).
71. J. Magrané, I. Hervias, M. S. Henning, M. Damiano, H. Kawamata, G. Manfredi, Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities. Hum. Mol. Genet. 18, 4552-4564 (2009).